An Exploratory Clinical Trial to Evaluate the Immunogenicity and Safety of One vs Two Doses of Quadrivalent Influenza Vaccine in Children Aged 3-8 Years Old
Latest Information Update: 17 Aug 2022
At a glance
- Drugs Influenza-virus-vaccine-quadrivalent-Sinovac-Biotech (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Sinovac Biotech
- 09 Aug 2022 Status changed from recruiting to completed.
- 15 Oct 2021 Status changed from not yet recruiting to recruiting.
- 17 Aug 2021 New trial record